These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25643809)

  • 1. Signalling mechanisms regulating phenotypic changes in breast cancer cells.
    Volinsky N; McCarthy CJ; von Kriegsheim A; Saban N; Okada-Hatakeyama M; Kolch W; Kholodenko BN
    Biosci Rep; 2015 Mar; 35(2):. PubMed ID: 25643809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M; Grijalva R; Yu D
    Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of mTOR in glioblastoma.
    Duzgun Z; Eroglu Z; Biray Avci C
    Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival.
    Coutant A; Rescan C; Gilot D; Loyer P; Guguen-Guillouzo C; Baffet G
    Hepatology; 2002 Nov; 36(5):1079-88. PubMed ID: 12395317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
    Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
    Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
    Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
    Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H; Akita RW; Sliwkowski MX; Maihle NJ
    Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
    Yang C; Liu Y; Lemmon MA; Kazanietz MG
    Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG; Hosick HL; Ethier SP
    J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells.
    Yue W; Wang J; Li Y; Fan P; Santen RJ
    Int J Cancer; 2005 Dec; 117(5):746-54. PubMed ID: 15957161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration.
    Xiong S; Grijalva R; Zhang L; Nguyen NT; Pisters PW; Pollock RE; Yu D
    Cancer Res; 2001 Feb; 61(4):1727-32. PubMed ID: 11245489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.
    Lucenay KS; Doostan I; Karakas C; Bui T; Ding Z; Mills GB; Hunt KK; Keyomarsi K
    Cancer Res; 2016 Apr; 76(8):2406-18. PubMed ID: 26928812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
    Menendez JA; Mehmi I; Lupu R
    Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.